Director

Susannah Gray, MBA

Director·4D Molecular Therapeutics, Inc.

About

Director since July 2020. Former EVP of Finance and Strategy of Royalty Pharma Management. Serves on the boards of AnaptysBio, Theravance Biopharma and Maravai LifeSciences.

Since 2020
Tenure 6 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director SM Shawn Cline Tomasello, MBA Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Director 2020–present Current role

Related

Company 4D Molecular Therapeutics, Inc. Company hub Person David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director Person John F. Milligan, Ph.D. Director and Executive Chairman Person Jacob Chacko, M.D., MBA Director Person Charles P. Theuer, M.D., Ph.D. Director Person Nancy Miller-Rich Director Person Shawn Cline Tomasello, MBA Director Person Glenn Sblendorio Director Person Kristian Humer Chief Financial Officer Person Christopher Simms Chief Commercial and Business Officer Person Scott Bizily, J.D., Ph.D. Chief Legal Officer and Corporate Secretary Person Ashoo Gupta Vice President, Finance and Controller Person Fariborz Kamal, Ph.D. Former President and Chief Operating Officer; Chief Technical Advisor
Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo